Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesCOSCIENS Biopharma Inc.

COSCIENS Biopharma Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-12T15:42:10.535921Z
Market Cap
8.64M

Momentum Score

…

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.83
Low
4.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cosciens Biopharma Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company with limited public disclosure that appears focused on advancing early-stage therapeutic candidates and building intellectual property. Long-term growth drivers may include favorable clinical results, regulatory approvals, strategic partnerships and successful commercialization, which could support value appreciation for investors.
Key investment risks include high probability of clinical and regulatory setbacks, no meaningful revenue and ongoing financing needs that could dilute shareholders, together with thin public information that complicates independent assessment.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
9.44M
Revenue Per Share
3.00
Gross Profit TTM
4.42M
Debt / Equity
0.18
ROE
-113.08%
Net Debt
-14.08M
ROCE
-54.21%
Diluted EPS TTM
-6.54

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -15.22M -4.37M 4.53M 2.59M 1.46M
Net income -15.31M -3.48M 3.45M 2.64M 1.46M
Selling general administrative 10.45M 5.59M 2.73M 2.54M 2.57M
Selling and marketing expenses - 0.03M 0.02M 0.04M 0.09M
Gross profit 6.80M 2.94M 8.56M 8.21M 5.98M
Reconciled depreciation 1.61M 1.44M 1.47M 1.48M 1.44M
Ebit -15.10M -4.23M 4.67M 2.71M 1.59M
Ebitda -13.49M -2.79M 6.14M 4.18M 3.04M
Depreciation and amortization 1.61M 1.44M 1.47M 1.48M 1.44M
Operating income -26.28M -4.63M 4.32M 2.43M 1.66M
Other operating expenses 40.06M 11.77M 10.25M 11.06M 10.20M
Interest expense 0.13M 0.14M 0.14M 0.12M 0.14M
Tax provision 0.08M -0.89M 1.08M -0.05M 0.00M
Interest income 0.44M 0.06M 0.14M - -
Net interest income 0.31M -0.08M 0.00M -0.16M -0.18M
Income tax expense 0.08M -0.89M 1.08M -0.05M 0.42M
Total revenue 13.78M 7.14M 14.57M 13.49M 11.86M
Total operating expenses 33.08M 7.57M 4.24M 5.78M 4.32M
Cost of revenue 6.98M 4.21M 6.02M 5.28M 5.88M
Total other income expense net 11.06M 0.26M 0.21M 0.16M -0.20M
Net income from continuing ops -15.31M -3.48M 3.45M 2.64M 1.46M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 35.07M 23.75M 27.80M 24.35M 22.92M
Intangible assets - 0.01M 0.01M 0.01M 0.01M
Other current assets 2.43M 0.29M 0.10M 0.15M 0.27M
Total liab 21.91M 2.71M 4.01M 2.61M 3.85M
Total stockholder equity 13.16M 21.04M 23.79M 21.74M 19.06M
Other current liab 4.29M 0.73M 1.67M 1.13M 1.31M
Common stock 22.49M 13.52M 12.30M 12.99M 12.95M
Capital stock 22.49M 16.72M 16.69M 16.56M 16.51M
Retained earnings -12.11M 4.36M 8.02M 5.08M 2.44M
Other assets - - - 0.00M 0.00M
Cash 16.39M 6.68M 10.18M 6.10M 4.21M
Total current liabilities 7.22M 1.31M 7.04M 7.76M 4.74M
Current deferred revenue 0.12M - 2.95M 4.81M 2.19M
Net debt -14.08M -4.98M -8.25M -4.03M -1.88M
Short term debt 0.27M 0.60M 0.39M 0.36M 0.25M
Short long term debt - - - - 0.07M
Short long term debt total 2.31M 1.70M 1.93M 2.08M 2.33M
Other stockholder equity 4.27M 3.16M 3.47M 3.67M 3.67M
Total current assets 23.98M 11.27M 15.17M 9.73M 7.10M
Net receivables 2.47M 0.29M 2.13M 1.68M 1.66M
Inventory 2.69M 4.01M 2.77M 0.07M 0.95M
Accounts payable 2.41M 0.28M - - -
Accumulated other comprehensive income -1.48M 4.35M 4.12M 4.40M 11.36M
Non currrent assets other 0.12M 0.75M 0.69M 0.66M 0.54M
Non current assets total 11.09M 12.48M 12.63M 14.62M 15.82M
Capital lease obligations 2.31M 2.25M 2.62M 2.65M 2.90M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 25.08M -0.73M -0.39M -0.79M -0.48M
Total cashflows from investing activities 25.08M -0.73M -0.30M -0.62M -0.38M
Total cash from financing activities -0.59M -0.36M -0.27M 50.59M 21.55M
Net income -15.31M -3.48M 3.45M 2.64M 1.46M
Change in cash 9.71M -3.51M 4.03M 1.89M 2.75M
Begin period cash flow 6.68M 10.19M 6.16M 4.21M 1.46M
End period cash flow 16.39M 6.68M 10.19M 6.10M 4.21M
Total cash from operating activities -14.57M -2.58M 5.23M 2.75M 3.49M
Depreciation 1.61M 1.47M 1.47M 1.48M 1.44M
Other cashflows from investing activities 0.21M -0.01M - -0.06M 0.11M
Change to inventory 1.59M -1.17M -1.06M -0.87M 1.24M
Change to account receivables -2.42M 1.79M -0.62M -0.14M 1.24M
Other cashflows from financing activities -0.01M 0.01M 0.06M 0.02M 0.00M
Capital expenditures 1.16M 0.72M 0.01M 0.56M 0.49M
Change in working capital -1.67M 0.06M -0.94M -1.16M 0.47M
Stock based compensation 0.46M 0.19M 0.07M 0.01M 0.11M
Other non cash items 0.27M 0.10M 0.10M 0.01M 0.02M
Free cash flow -15.73M -3.30M 4.92M 2.20M 3.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

222 Bay Street, Toronto, ON, Canada, M5K 1E7

https://www.cosciensbio.com

40

Name Title Year Born
Mr. Giuliano La Fratta Senior VP of Finance & CFO NA
Mr. Michel Regnier P. Eng. Senior VP of Technical operations, MD of Ceapro Inc. & CTO NA
Dr. Michael Teifel Ph.D. Senior Vice President of GmbH & Chief Scientific Officer NA
Dr. Matthias Gerlach Senior Vice President Manufacturing and Supply Chain & Head of Production NA
Ms. Anna Elizabeth Biehn Chief Executive Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…